Bronx, New York Clinical Trials

A listing of Bronx, New York clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 420 clinical trials
Study in Subjects With Relapsed/Refractory Follicular Lymphoma

This is a multicenter, double-blind, active-controlled, randomized, 3-stage, biomarker enrichment design featuring early futility stopping and sample-size re-estimation with safety run-in designed to evaluate the efficacy and safety of tazemetostat in combination with R2 in subjects with R/R FL, who have completed at least 1 prior systemic chemotherapy, immunotherapy, or …

lymphoma
bone marrow procedure
rituximab
ibritumomab tiuxetan
systemic therapy
Memorial Sloan-Kettering Cancer Cente
 (4.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +7 other locations
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/r FL or MZL. The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good …

b-cell lymphoma
malt
lymphoma
systemic therapy
cyclophosphamide
Memorial Sloan Kettering Cancer Center
 (4.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +35 other locations
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during …

small cell lung cancer
maintenance therapy
lung cancer
carboplatin
solid tumour
Mount Sinai - PRIME; Icahn School of Medicine at Mount Sinai
 (2.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +146 other locations
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.

hemodynamic evaluation
septal defect
macitentan
hypertension
macitentan 10 mg
Columbia University
 (1.8 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +210 other locations
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine Cyclophosphamide and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a cumulative illness rating scale [CIRS]/score of 6 and a normal creatinine clearance of 70 mL/min) …

myelodysplastic syndrome
bone marrow procedure
rituximab
blood transfusion
venetoclax
Regional Cancer Care Associates
 (8.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +50 other locations
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers

The primary objective of this study is to demonstrate the non-inferiority of the vaccine seroresponse to meningococcal serogroups A, C, Y, and W following administration of 2 doses of MenACYW conjugate vaccine compared to 2 doses of MENVEO when given concomitantly with routine pediatric vaccines to infants and toddlers 6 …

Investigational Site Number 8400069
 (3.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +47 other locations
Phase 2 Study of SAR439859 Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer (AMEERA-3)

Primary Objective: To determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer. Secondary Objectives: To compare the overall survival in the 2 treatment arms To assess the objective …

metastasis
advanced breast cancer
oestrogen receptor positive breast cancer
breast cancer
estrogen receptor-positive breast cancer
Investigational Site Number 8400025
 (8.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +130 other locations
Aging and Information Processing

The purpose of our study is to better understand functional differences in brain activity between healthy aging and neurodegenerative conditions, such as Alzheimer's Disease. To do this, our lab uses a noninvasive and inexpensive technique to collect brain measurements called electroencephalogram (EEG). By recording EEG while participants do certain memory …

AutoSite12071
 (6.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +8 other locations
Formal Test Trial 500 Site & User

Test comment here

A123
 (5.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis (FREVIVA)  

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at …

Holy Name Medical Center Site Number : 8400101
 (6.8 away)
  • 0 views
  • 04 Mar, 2025
  • +58 other locations